Within only six months of the manufacturer's submission of the application, FDA approved a new drug to treat two bone disorders: osteoporosis in postmenopausal women and Paget's disease.
Fosamax (alendronate) is the first bisphosphonate drug approved for osteoporosis, providing an alternative to estrogen and calcitonin, previously approved treatments. Fosamax was approved last Sept. 29. Other bisphosphonates were previously approved for Paget's disease.
Osteoporosis is a condition of low bone mass and reduced bone strength that leads to fractures of the spine, wrist and hip. In Paget's disease, normal bone is replaced with poor quality bone.
In two three-year studies of more than 900 patients, bone strength increased 8.16 percent in patients receiving alendronate and decreased 0.65 percent in those receiving a placebo. In addition to the drug therapy, patients received a daily dietary calcium supplement. Adverse effects associated with the drug include nausea, heartburn, flatulence, and abdominal pain.
Fosamax should be used in conjunction with an adequate diet, including enough vitamin D and calcium, and an exercise program. The drug should be taken in the morning at least a half hour--preferably a full hour-before eating or taking other medication.
The manufacturer is Merck and Co., of West Point, Pa.
COPYRIGHT 1995 U.S. Government Printing Office
COPYRIGHT 2004 Gale Group